



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

13.02.2024

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting of Godavari Drugs Limited (the Company) held on Tuesday 13th February, 2024

Ref: Reg. 30 read with Reg. 33 of SEBI (LODR) Regulations, 2015

We wish to inform you that the Board of Directors of the Company at their meeting held on today, i.e. February 13, 2024 has, inter alia, transacted the following business:

1. Considered and approved the un-audited Financial Results for the quarter ended 31st December, 2023 with limited review report as recommended by the Audit Committee and reviewed by the Statutory Auditors is attached as **Annexure - A**
2. On the recommendation of the Nomination and Remuneration Committee, Board has considered and approved, the appointment of Mr. Dinesh Udpa (DIN: 10503106) as an 'Additional Director' in the category of Non-Executive - Independent Director' of the Company. Brief Profile of Mr. Dinesh Udpa, in terms of the SEBI Listing Regulations, is annexed herewith as **Annexure - B**

The Board Meeting Commenced at 04:30 P.M and concluded at 05:30 PM

A Copy of said results together with the limited review report is enclosed herewith for the Third quarter ended December 31, 2023 are enclosed herewith.

These are also made available on the website of the company at www.godavaridrugs.com

This is for your information and records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer
Membership Number : A53326

GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Nine Months ended on			Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	30.09.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	4311.05	3954.25	3915.81	11807.18	7496.13	12225.51	15962.48
2	Other Income	5.02	0.35	29.86	50.58	45.56	49.73	65.53
3	Total Revenue from operations (1+2)	4316.07	3954.60	3945.67	11857.76	7541.69	12275.24	16028.01
4	Expenses							
	(a) Cost of materials consumed	3294.56	3035.42	2735.08	8,974.32	5,679.76	10286.77	13782.07
	Changes in inventories of finished goods & work-in-progress	138.02	40.27	475.32	340.62	202.60	-362.92	-976.30
	(b)							
	(c) Employee benefits expense	127.30	119.06	119.69	368.31	241.01	350.40	484.04
	(d) Depreciation & amortization expense	49.54	49.38	51.42	146.30	96.76	144.77	194.35
	(e) Finance Costs	127.48	129.81	109.92	368.27	240.79	289.79	392.73
	(f) Other Expenses	399.22	453.23	358.80	1240.84	841.62	1227.42	1680.59
	Total expenses	4136.12	3827.17	3850.23	11438.66	7302.54	11936.23	15557.48
5	Profit before exceptional Items and tax	179.95	127.43	95.44	419.10	239.15	339.01	470.53
6	Exceptional items	-5.83	-	-	-5.83	-	-	22.95
7	Profit before Tax (5-6)	174.12	127.43	95.44	413.27	239.15	339.01	493.48
8	Tax expense	-52.03	-41.85	-28.53	-124.56	-72.53	-93.56	-114.89
9	Net Profit for the period (7-8)	122.09	85.58	66.91	288.71	166.62	245.45	378.58
10	Other Comprehensive Income							
	(i) Items that will not be reclassified to profit or loss							
	(ii) Income tax relating to Items that will not be reclassified to profit or loss							
	(iii) Items that will be reclassified to profit or loss							
	(iv) Income tax relating to Items that will be reclassified to profit or loss							
11	Total Comprehensive Income (9+10)	122.09	85.58	66.91	288.71	166.62	245.45	378.58
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)							2588.67
14	Earnings per share (of Rs.10/- each) (not annualized)							
	(a) Basic	1.62	1.14	0.89	3.83	2.21	3.26	5.03
	(b) Diluted	1.62	1.14	0.89	3.83	2.21	3.26	5.03

1.The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 13.02.2024

2.The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable

3.The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.

4.Corresponding figures in previous year / period have been regrouped wherever considered necessary.



For GODAVARI DRUGS LIMITED
(Signature)
Mohit Jaju
Whole Time Director & CFO
DIN: 03405414

Place: Secunderabad
Date: 13.02.2024

**Independent Auditor's Review Report on unaudited quarterly financial results of
Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015**

To,
The Board of Directors
Godavari Drugs Limited
Hyderabad

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and nine months ending on December 31, 2023 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S



Ayyadevara Srinivas
Proprietor
ICAI Membership No. 028803
Hyderabad Feb 13, 2024.
UDIN: 24028803BKHJGP5600





GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Annexure - B

Disclosure required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, with regard to appointment of Independent Directors is given herein under: -

S. No	Particulars	Remarks
1	Name	Mr. Dinesh Udpa
2	Reason for change viz appointment, resignation, removal, death or otherwise	Appointment
3	Date of appointment/ cessation (as applicable) & terms of appointment	13-02-2024
4	Brief Profile (in case of appointment)	Mr. Dinesh Udpa is being appointed as Non-Executive Independent Director of the company. He holds Bachelor of Technology in Chemical Engineering from University College of Technology, Osmania University, Hyderabad and a Master of Engineering in Chemical Engineering from Indian Institute of Science, Bangalore. He has a decade of experience in the project, engineering, and company management. Extensive experience in basic engineering, detailed value engineering, procurement of equipment and materials, schedule, and cost control, doing due diligence, coordination with design engineers, vendors, and construction teams
5	Disclosure of relationship between directors (in case of appointment of Director)	He does not have relation either financially or otherwise with any of the existing Directors/ Key Managerial Personnel of the Company
6	Names of the listed Company in which the resigning director holds directorships, indicating the category of directorship & membership of board committees	Nil
7	Shareholding if any in the Company	Nil